Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 812 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Assessment, Geriatric Clear all
Completed Phase 3 Interventional Results available

Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza

NCT02635724
View directory record Official record
Conditions
Influenza
Interventions
Peramivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Brooksville, Florida • Lakeland, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 15, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Results available

A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)

NCT03452488
View directory record Official record
Conditions
Sarcopenia, Gait Disorders in Old Age, Muscle Weakness
Interventions
BIO101, Placebo
Drug
Lead sponsor
Biophytis
Industry
Eligibility
65 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
19
States / cities
Banning, California • Garden Grove, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 15, 2026, 8:38 PM EDT
Withdrawn Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis

NCT05316220
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Mesalamine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 15, 2026, 8:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of Adhesion and Dermal Tolerability of EMSAM

NCT00531596
View directory record Official record
Conditions
Healthy
Interventions
EMSAM (Selegiline Transdermal System) 6mg/24Hr, EMSAM (Selegiline Transdermal System) 9mg/24Hr, EMSAM (Selegiline Transdermal System) 12mg/24hr
Drug
Lead sponsor
Somerset Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Scottsdale, Arizona • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2007 · Synced Oct 15, 2026, 8:38 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older

NCT06134804
View directory record Official record
Conditions
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Interventions
ExPEC9V, Placebo, HD quadrivalent influenza vaccine
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
959 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
24
States / cities
Huntsville, Alabama • Mobile, Alabama • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 15, 2026, 8:38 PM EDT
Completed Phase 4 Interventional Results available

Study to Assess DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Forearms and Hands

NCT01910831
View directory record Official record
Conditions
Purpura
Interventions
DerMend Moisturizing Bruise Formula, Non-active placebo control
Drug
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
60 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 15, 2026, 8:38 PM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery

NCT06271265
View directory record Official record
Conditions
Postoperative Pain
Interventions
EXPAREL, bupivacaine
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
0 Years to 6 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Indianapolis, Indiana • St Louis, Missouri • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 15, 2026, 8:38 PM EDT
Completed Not applicable Interventional Results available

Making Better Lives: Patient-Focused Care for Low Back Pain (LBP)

NCT02697435
View directory record Official record
Conditions
Chronic Low Back Pain, Hip Ostearthritis, Myofascial Pain Syndrome, Fibromyalgia, Depression, Maladaptive Coping, Lumbar Spinal Stenosis, Insomnia, Sacroiliac Joint Pain, Lateral Hip and Thigh Pain, Anxiety, Dementia, Recent Leg Length Discrepancy
Interventions
Patient-Centered Care, Imaging-Directed Care
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years to 89 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 15, 2026, 8:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly Japanese, and Healthy Younger Adult Japanese Subjects

NCT02857777
View directory record Official record
Conditions
Healthy
Interventions
Esketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 15, 2026, 8:38 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants

NCT05584202
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273.214, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
2 Months to 6 Months
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
39
States / cities
Bessemer, Alabama • Birmingham, Alabama • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 15, 2026, 8:38 PM EDT
Completed Phase 1 Interventional Results available

A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma

NCT06702462
View directory record Official record
Conditions
Asthma
Interventions
HFA-152A propellant, HFA-134A propellant
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
3
States / cities
Marlton, New Jersey • Huntersville, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 15, 2026, 8:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Seasonal Patterns of Stress, Diet and Physical Activity - Life in All Seasons (LENAS)

NCT01674296
View directory record Official record
Conditions
Obesity, Stress, Feeding Behavior, Physical Activity
Interventions
Not listed
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
40 Years to 60 Years · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Oct 15, 2026, 8:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

NCT02453022
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet, Prilosec (omeprazole) 40mg Delayed-Release capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 15, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas

NCT04917861
View directory record Official record
Conditions
Zika Virus
Interventions
mRNA-1893, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
808 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
3
States / cities
Sioux City, Iowa • Lenexa, Kansas • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 15, 2026, 8:38 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation

NCT02766777
View directory record Official record
Conditions
Constipation - Functional
Interventions
Lubiprostone
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
13
States / cities
Fayetteville, Arkansas • Peoria, Illinois • Shreveport, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated May 15, 2020 · Synced Oct 15, 2026, 8:38 PM EDT
Completed Not applicable Interventional Results available

Drug Reduction in Older Patients: The DROP Trial

NCT03722017
View directory record Official record
Conditions
Geriatric Assessment, Frail Elderly, Skilled Nursing Facilities, Patient-centered Care
Interventions
Deprescribing intervention
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 15, 2026, 8:38 PM EDT
Completed Not applicable Interventional

LCI-GER-NOS-TAB-001: Tablet for Geriatric Assessment

NCT03419468
View directory record Official record
Conditions
Self Geriatric Assessment Measure (SGAM)
Interventions
Self Geriatric Assessment Measure (SGAM)
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
70 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 15, 2026, 8:38 PM EDT
Completed Not applicable Interventional

Impact of Physical Activity on Biomarker of Aging and Body Composition Among Breast Cancer Survivors Age 65 and Older

NCT02328313
View directory record Official record
Conditions
Breast Cancer, Aging, Physical Activity
Interventions
Walk with Ease Program
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
65 Years and older · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Oct 15, 2026, 8:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Performance Evaluation and Research for Older Adults Requiring Major Surgery

NCT00487890
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
65 Years and older
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 15, 2026, 8:38 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10

NCT00754013
View directory record Official record
Conditions
Down Syndrome, Cognitive Dysfunction
Interventions
Aricept (Donepezil hydrochloride), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
6 Years to 10 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
San Antonio, Texas • Herndon, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 15, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

NCT00799864
View directory record Official record
Conditions
HIV-1
Interventions
Rilpivirine, Zidovudine, Abacavir, Tenofovir disoproxil fumarate, Lamivudine, Emtricitabine
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
6 Years to 17 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
Syracuse, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 15, 2026, 8:38 PM EDT
Terminated Phase 2 Interventional Results available

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation

NCT00953706
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
34
States / cities
Birmingham, Alabama • Anchorage, Alaska • Oakland, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2015 · Synced Oct 15, 2026, 8:38 PM EDT
Completed Phase 2 Interventional

Efficacy Study of EVT 201 in the Treatment of Elderly Patients With Daytime Sleepiness

NCT00401284
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
EVT 201
Drug
Lead sponsor
Evotec Neurosciences GmbH
Industry
Eligibility
65 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2008 · Synced Oct 15, 2026, 8:38 PM EDT
Completed Phase 1 Interventional Results available

Text Messaging to Increase Activity in Midlife

NCT04849052
View directory record Official record
Conditions
Middle Aged
Interventions
MASTERY, Attentional Control
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 64 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 15, 2026, 8:38 PM EDT